Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides
22 juin 2021 07h00 HE
|
INNATE PHARMA
First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data support continued development of lacutamab for...
Innate Pharma Présentera les Progres de sa Strategie Lors d'un Événement Virtuel a Destination des Investisseurs
16 juin 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, 16 juin 2021 (GLOBE NEWSWIRE) -- La Société mettra en avant les données de lacutamab dans le mycosis fongoïde et partagera des données issues de sa plateforme de NK cell...
Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy
16 juin 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, June 16, 2021 (GLOBE NEWSWIRE) -- Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKETTM ...
Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy
16 juin 2021 01h00 HE
|
INNATE PHARMA
MARSEILLE, France, June 16, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual...
Nouveau Nombre D’Actions et de Droits de Vote d’Innate Pharma au 1er Juin 2021
14 juin 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, 14 juin 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate...
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2021
14 juin 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, June 14, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2021
14 juin 2021 01h00 HE
|
INNATE PHARMA
MARSEILLE, France, June 14, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
Innate Pharma Presentera des Données Issues de sa Plateforme de NK Cell Engagers de Nouvelle Generation au Congrés Annuel de la FOCIS 2021
10 juin 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, 10 juin 2021 (GLOBE NEWSWIRE) -- La plateforme propriétaire de NK cell engagers multi-spécifiques, ANKETTM, contribuera à générer une nouvelle vague de molécules...
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting
10 juin 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, June 10, 2021 (GLOBE NEWSWIRE) -- Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy molecules ANKET is first NK cell engager...
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting
10 juin 2021 01h00 HE
|
INNATE PHARMA
Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy moleculesANKET is first NK cell engager technology to engage NKp46, CD16, IL-2 variant and tumor...